

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-16 (cancelled).

17 (previously presented). A pharmaceutical and/or veterinary solid implant formulation comprising about 2-15% (w/w) of at least one GnRH agonist peptide (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin, wherein said GnRH agonist peptide is other than deslorelin.

18 (previously presented). A formulation according to claim 17, comprising about 5-10% (w/w) of the GnRH agonist peptide (on an active basis), about 0.5-1.5% (w/w) lecithin and about 89-94% (w/w) stearin.

19 (previously presented). A formulation according to claim 18, comprising about 5% (w/w) of the GnRH agonist peptide (on an active basis), 1% (w/w) lecithin and the 94% (w/w) stearin.

20 (previously presented). A formulation according to claim 18, comprising about 5% (w/w) of the GnRH agonist peptide (on an active basis), 2% (w/w) lecithin and 93% (w/w) stearin.

21 (cancelled).

22 (previously presented). A formulation according to claim 17, wherein the lecithin and stearin are in non-crystalline form.

23-30 (cancelled).